Pascal Deschatelets - 21 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
21 Apr 2022
Net transactions value
-$167,040
Form type
4
Filing time
02 May 2022, 20:05:25 UTC
Previous filing
14 Feb 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1,875 -0.21% $0.000000 891,775 21 Apr 2022 Direct F1
transaction APLS Common Stock Options Exercise $10,680 +4,000 +0.45% $2.67* 895,775 29 Apr 2022 Direct F2
transaction APLS Common Stock Sale $177,720 -4,000 -0.45% $44.43 891,775 29 Apr 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -11,250 -100% $0.000000* 0 21 Apr 2022 Common Stock 11,250 $44.90 Direct F3, F4
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4,000 -1.1% $0.000000 364,999 29 Apr 2022 Common Stock 4,000 $2.67 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F3 This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F4 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
F5 This stock option was granted on 12/5/2013 and is fully vested.